Company news
Artelo Biosciences, Inc. news in 2020
Artelo Biosciences, Inc.'s news releases, calls and decks from 2020, newest first.
Artelo Biosciences Files Patent Application for New Formulation of ART27.13
December 8, 2020
Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D., Ph.D., to Board of Directors
December 1, 2020
Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss
November 15, 2020
Artelo Biosciences Reports Fourth Quarter and Fiscal 2020 Year-End Financial Results and Provides Business Update
November 3, 2020
Artelo Biosciences Files Patent on Use of Fatty Acid Binding Protein 5 Inhibitors for Treating Psychological Disorders
October 20, 2020
Artelo Biosciences, Inc. Announces Closing of $7.6 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option
October 13, 2020
Artelo Biosciences, Inc. Announces Pricing of $6.6 Million Upsized Underwritten Public Offering
October 8, 2020
Artelo Biosciences Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia
September 28, 2020
Artelo Biosciences Reports Third Quarter Fiscal Year 2020 Financial Results and Provides Business Update
July 13, 2020
Artelo Biosciences Expands Stony Brook Commercial License Agreement for FABP5 Platform for Development of Lead Cancer, Pain and Inflammation Compounds
June 28, 2020
Artelo Biosciences Awarded Composition of Matter Patent for Novel CBD Cocrystal
May 11, 2020
Artelo Biosciences Reports Second Quarter Fiscal Year 2020 Financial Results and Provides Business Update
April 13, 2020
Artelo Biosciences Announces NCI Grant of $4.2 Million to Stony Brook University to Advance FABP5 Inhibitor Cancer Program
February 2, 2020
Artelo Biosciences Reports First Quarter Fiscal Year 2020 Financial Results and Provides Business Update
January 13, 2020